1. Neurological Disease

Neurological Disease

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-P10394
    DP32 2376306-14-6 98%
    DP32 is a bifunctional compound that contains an opioid receptor (MOP) agonist and a neuropeptide FF receptor (NPFFR) antagonist. DP32 can be used in analgesia-related research.
    DP32
  • HY-P10395
    DP50 98%
    DP50 is a bifunctional compound that contains an opioid receptor (MOP) agonist and a neuropeptide FF receptor (NPFFR) antagonist. DP50 can be used in analgesia-related research.
    DP50
  • HY-P10404
    PDpep1.3 2942277-55-4 98%
    PDpep1.3 is a peptide inhibitor of α-synuclein that disrupts the direct interaction between α-synuclein and CHarged Multivesicular body Protein 2B (CHMP2B). As a result, PDpep1.3 restores the degradation function of endosomes and lysosomes, reduces the protein level and aggregation of α-synuclei, and protects dopaminergic neurons from α-synuclei-mediated degeneration. PDpep1.3 can be used to study neurodegenerative diseases and protein-protein interactions.
    PDpep1.3
  • HY-P10416
    Q14 98.51%
    Q14 is a polypeptide derived from the USP30 (ubiquitin specific peptidase 30) transmembrane (TM) domain with the ability to inhibit the deubiquitination activity of USP30 (IC50=57.2 nM). Q14 reduces USP30 activity by inhibiting the interaction between the USP30 transmembrane domain and its catalytic domain. Q14 peptide contains the LC3 interaction region (LIR) motif, which enables it to bind to the LC3 and accelerate the formation of autophagosomes, thereby promoting mitophagy. Q14 can be used in the study of neurodegenerative diseases as well as mitochondrial quality control and cell metabolism.
    Q14
  • HY-P10427
    DV1 98%
    DV1 is a CXCR4 inhibitor with anti-proteolytic properties that specifically blocks the binding of SDF-1α to its receptor. DV1 inhibits the migration of breast cancer cells and enables the targeted delivery of avidin-PLGA nanoparticles to CXCR4-expressing cancer cells. DV1 not only effectively suppresses the progression of metastatic breast cancer in mouse models, but also preferentially accumulates in brain tumor tissues rather than normal brain tissues, showing potential for inhibiting intracranial tumor metastasis. As a humoral immune stimulant, DV1 induces the production of specific IgG, neutralizing antibodies and cellular immune responses, thereby providing the host with protection against lethal challenges. DV1 has been applied to studies on CXCR4-expressing cancers, glioblastoma, dengue fever and other related diseases.
    DV1
  • HY-P10435
    KEMPFPKYPVEP 1393589-51-9 98%
    KEMPFPKYPVEP is a 12-amino acids neuropeptide, which upregulates levels of dopamine (DA) and norepinephrine (NE) in the prefrontal cortex, exhibits spatial and object recognition memory promoting ability in Scopolamine (HY-N0296)-induced amnesia mouse model.
    KEMPFPKYPVEP
  • HY-P10464
    Tat-AKAP79 (326-336) 98%
    TAT-AKAP79 326-336 is a cytoosmotic peptide. TAT-AKAP79 326-336 mimics a specific region on the AKAP79 protein that binds to TRPV1 ion channels (amino acid sequence 326-336). TAT-AKAP79 326-336 inhibits the sensitization of TRPV1 and reduce the overresponse of TRPV1 channels to stimuli caused by the activation of cellular kinases such as protein kinase A (PKA) and protein kinase C (PKC) by inflammatory mediators. TAT-AKAP79 326-336 can be used to study the mechanism of pain transduction and inflammatory hyperalgesia.
    Tat-AKAP79 (326-336)
  • HY-P10487
    APP669-711 98%
    APP669-711 is a peptide segment from amino acid 669 to amino acid 711 of amyloid precursor protein (APP). APP669-711 can be used to diagnose the amyloid deposition in the brain, and is a biomarker for Alzheimer's disease (AD) research.
    APP669-711
  • HY-P10498
    [Des-Tyr1]-gamma-Endorphin 67810-56-4 98%
    [Des-Tyr1]-gamma-Endorphin is a neuropeptide, which can be found in human cerebrospinal fluid. [Des-Tyr1]-gamma-Endorphin exhibits antidepressant efficacy, facilitates the extinction of active avoidance and attenuates the passive avoidance behavior in rats.
    [Des-Tyr1]-gamma-Endorphin
  • HY-P10500
    NX210 216682-41-6 98%
    NX210 is a dodecapeptide derived from the SCO-spondin protein. NX210 can increase cell survival and induce neurite outgrowth, and participate in cell-cell and cell-matrix interactions. NX210 can be used in research on spinal cord injury recovery.
    NX210
  • HY-P10525
    MBP Ac1-9 (4Y) 167278-49-1 98%
    MBP Ac1-9 (4Y) is a synthetic peptide derived from a fragment of myelin basic protein (MBP) that has undergone specific chemical modifications. MBP Ac1-9 (4Y) is able to form a complex with the MHC class II molecule I-Au and activate specific T cell receptor (TCR), thus playing a role in the pathogenesis of experimental autoimmune encephalomyelitis (EAE). MBP Ac1-9 (4Y) can be used to study autoimmune diseases, especially those involving the central nervous system, such as multiple sclerosis.
    MBP Ac1-9 (4Y)
  • HY-P10534
    ccβ 873582-78-6 98%
    CCβ is a simple 17-amino acid peptide designed in research. CCβ is able to mimic the conformational transition of proteins from α-helix to β-sheet, which is a key step in the aggregation of proteins associated with many diseases, such as Alzheimer's disease and prion disease. CCβ can be used to study diseases related to protein aggregation.
    ccβ
  • HY-P10545
    [D-His26]-Neuropeptide Y, human, rat 98%
    [D-His26]-Neuropeptide Y, human, rat is a synthetic variant of neuropeptide Y (NPY). [D-His26]-Neuropeptide Y, human, rat acts as a Y1R agonist that can prevent the development of anxiety, social impairment, and depressive symptoms, and has the potential to be used as an early intervention treatment for post-traumatic stress reactions.
    [D-His26]-Neuropeptide Y, human, rat
  • HY-P10549
    NGFFFamide 1219926-09-6 98%
    NGFFFamide is a muscle-active neuropeptide found in sea urchins. NGFFFamide regulates muscle activity by directly interacting with receptor proteins on muscle cells, or indirectly by stimulating nerves or other cell types to release muscle-active factors. NGFFFamide can be used to study muscle contraction and relaxation.
    NGFFFamide
  • HY-P10555
    (D-Arg2, Sar 4)-Dermorphin (1-4) 90549-86-3 98%
    (D-Arg2, Sar 4)-Dermorphin (1-4) is a tetrapeptide derivative of the peptide Dermorphin (HY-P0244) found in amphibian skin. (D-Arg2, Sar 4)-Dermorphin (1-4) has significant analgesic effects by binding to the μ-opioid receptor (MOR) in the body. (D-Arg2, Sar 4)-Dermorphin (1-4) can be used in the development of analgesic drugs.
    (D-Arg2, Sar 4)-Dermorphin (1-4)
  • HY-P10578
    SEN 304 906357-94-6 98%
    SEN 304 is an Aβ aggregation inhibitor. SEN 304 can bind directly to Aβ(1-42), delay β-sheet formation and promote aggregation of toxic oligomers into a nontoxic form. SEN 304 can be used for research of Alzheimer’s disease.
    SEN 304
  • HY-P10595
    Antho-Rwamide II 118904-15-7 98%
    Antho-Rwamide II is a neuropeptide that can be isolated from the sea anemone Anthopleura elegantissima. Antho-Rwamide II can induce contraction of the endothelial muscles of the sea anemone and participate in neurotransmission. Antho-Rwamide II can be used to explore the function of the nervous system in invertebrates.
    Antho-Rwamide II
  • HY-P10599
    Scyliorhinin I 103425-21-4 98%
    Scyliorhinin I is a tachykinin-1 (NK-1) and tachykinin-2 (NK-2) receptor agonist with a Ki value of 0.9 nM for rat submandibular gland NK-1 receptor and 2 nM for hamster bladder NK-2 receptor. Scyliorhinin I has the ability to contract the longitudinal muscles of the guinea pig ileum.
    Scyliorhinin I
  • HY-P1060A
    LPYFD-NH2 TFA 98%
    LPYFD-NH2 TFA, a pentapeptide, exerts some inhibitory effect on the aggregation of Aβ(1-42). LPYFD-NH2 TFA can be used for the research of Alzheimer’s disease.
    LPYFD-NH2 TFA
  • HY-P10611
    [D-Ser14]-Humanin 570382-85-3 98%
    [D-Ser14]-Humanin is a bioactive peptide in which the Ser14 residue of Humanin (HY-P1928) is changed from L-form to D-form. [D-Ser14]-Humanin has potent inhibitory activity against the fibrillation of amyloid-β. Humanin (HY-P1928) inhibits the aging-related death of various cells caused by amyloid fibrils and oxidative stress, and [D-Ser14]-Humanin has better cell protection activity than Humanin (HY-P1928). [D-Ser14]-Humanin can be used in the study of Alzheimer's disease.
    [D-Ser14]-Humanin
Cat. No. Product Name / Synonyms Application Reactivity